## VERTEX PHARMACEUTICALS INC.

ISIN: **US92532F1003** WKN: **92532F100** 

### Overview



General attributes		
ISIN	US92532F1003	
Symbol	VRTX	
Exchange	Vienna Stock Exchange	
Currency	EUR	
Sector	Chemical / Pharmaceutical / Health	
Security type	Stock	
Market cap (m)	94,581 EUR	
Benchmark	S&P 500	

Market data	
Bid (Bid size)	-
Ask (Ask size)	-
Open	372.95 EUR
High	372.95 EUR
Low	368.20 EUR
Close (prev. day)	369.10 EUR
VWAP	381.35 EUR
Volume (pcs)	0
Trading volume	0.00
Number of trades	2
Last size	0



PDF Downloads	
Company report: VERTEX PHARMACEUTICALS INC.	



Information about previous performance does not guarantee future performance. **Source:** FactSet

#### **Recent research**

on instrument	on sector	on market	
Date		Headline	Download
2024/04/03	80. J.S. 821 TS	Global Equity Ratings	
2024/03/13	8. LØ Ø1 1%	Global Equity Ratings	
2024/02/22	8. J.B 81 TS	Global Equity Ratings	
2024/02/14	8. LØ Ø1 1%	Global Equity Ratings	
2024/01/23	80 Jan 27 Jan	Global Equity Ratings	.≛.




# **Details**

<b>2024/04/10</b> 17:32	2:22	
<b>Price 368.20</b> EUR		
Difference	0	-0.24% (-0.90)

General attributes		
ISIN	US92532F1003	
Symbol	VRTX	
Exchange	Vienna Stock Exchange	
Currency	EUR	
Sector	Chemical / Pharmaceutical / Health	
Security type	Stock	
Market cap (m)	94,581 EUR	
Benchmark	S&P 500	

Market data	
Bid (Bid size)	-
Ask (Ask size)	-
Open	372.95 EUR
High	372.95 EUR
Low	368.20 EUR
Close (prev. day)	369.10 EUR
VWAP	381.35 EUR
Volume (pcs)	0
Trading volume	0.00
Number of trades	2
Last size	0

Performance and Risk				
	6m	1Y	3Y	
Perf (%)	+8.28%	+24.83%	+106.62%	
Perf (abs.)	+28.15	+73.25	+190.00	
Beta	0.76	0.69	0.60	
Volatility	24.62	22.30	26.16	



Information about previous performance does not guarantee future performance.  $\textbf{Source:} \ \textbf{FactSet}$ 

Price data	
Ø price 5 days   Ø volume 5 days (pcs.)	372.30 EUR (0)
Ø price 30 days   Ø volume 30 days (pcs.)	381.82 EUR (10)
Ø price 100 days   Ø volume 100 days (pcs.)	373.61 EUR (24)
Ø price 250 days   Ø volume 250 days (pcs.)	343.18 EUR (24)
YTD High   date	416.85 EUR (2024/01/30)
YTD Low   date	368.20 EUR (2024/04/10)
52 Weeks High   date	416.85 EUR (2024/01/30)
52 Weeks Low   date	289.10 EUR (2023/04/26)

All listings for VERTEX PHARMACEUTICALS INC.					
Exchange 🖶	Date	Time	Price	Trading volume (mio.)	Number of trades
Xetra	2024/ 04/10	17:35	368.70 EUR	0.00	1
Vienna Stock Exchange	2024/ 04/10	17:32	368.20 EUR	0.00	2
Tradegate	2024/ 04/10	22:26	370.05 EUR	0.10	23
Stuttgart	2024/ 04/10	21:05	368.80 EUR	0.00	4
Nasdaq	2024/	22:00	397.58 USD	407.51	32,689



	04/10				
Munich	2024/ 04/10	08:00	371.85 EUR	0.00	2
London Stock Exchange	2024/ 04/04	16:36	409.12 USD	0.00	1
Hanover	2024/ 04/10	20:03	367.65 EUR	0.01	2
Hamburg	2024/ 04/10	08:11	372.10 EUR	0.00	3
Frankfurt	2024/ 04/10	21:06	368.90 EUR	0.01	3
Euronext Milan MTF Trading After Hours	2024/ 02/28	19:24	393.60 EUR	0.00	1
Euronext Milan MTF Global Equity Market	2024/ 04/10	17:44	368.25 EUR	0.00	1
Duesseldorf	2024/ 04/10	19:30	367.75 EUR	0.00	7
Berlin	2024/ 04/10	08:08	371.95 EUR	0.00	2
BX Swiss	2024/ 04/10	18:00	365.042 CHF	0.00	1



## Company profile

### **Company Logo**



#### **Contact Details**

VERTEX PHARMACEUTICALS INC.

- -

50 Northern Avenue - 02210 Boston

Telefon: +1-617-341-6100

Fax: +

E-mail: mediainfo@vrtx.com

### **PDF Downloads**

Company report: VERTEX PHARMACEUTICALS INC.



£

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Members of Mana	gement Board
Jeffrey Leiden	Chairman of Board of Directors
Alan Garber	Member of Board of Directors
Sangeeta Bhatia	Member of Board of Directors
Bruce Sachs	Member of Board of Directors
Diana McKenzie	Member of Board of Directors
Lloyd Carney	Member of Board of Directors
Michel Lagarde	Member of Board of Directors
Nancy Thornberry	Member of Board of Directors
Suketu Upadhyay	Member of Board of Directors
Terrence Kearney	Member of Board of Directors
Reshma Kewalramani, M.D.	Chairman of Managing Board
David Altshuler	Member of Executive Committee
Jeffrey Leiden	Member of Executive Committee
Amit K. Sachdev	Member of Executive Committee
Bastiano Sanna, Ph.D.	Member of Executive Committee
Carmen Bozic, M.D.	Member of Executive Committee
Charles F. Wagner, Jr.	Member of Executive Committee
Damian Wimot	Member of Executive Committee
Joy Liu	Member of Executive Committee
Ludovic Fenaux	Member of Executive Committee
Mark Bunnage	Member of Executive



	Committee
Michael Partridge	Member of Executive Committee
Mike Tirozzi	Member of Executive Committee
Nia Tatsis, Ph.D.	Member of Executive Committee
Nina Devlin	Member of Executive Committee

